Search Result

Pathways Recommended:	TGF-beta/Smad Antibody-drug Conjugate/ADC Related

Results for "

Amyloid Beta/Aβ Antibody

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (25) Akt (1) CCR (1) ERK (1) p38 MAPK (1) Tau Protein (1) Transmembrane Glycoprotein (1) Trk Receptor (1)
By Research Areas:	Cancer (1) Inflammation/Immunology (5) Neurological Disease (25)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Antibodies

Targets Recommended: Amyloid-β ADC Antibody Antibody-Drug Conjugates (ADCs) Adrenergic Receptor TGF-beta/Smad Antibody-Oligonucleotide Conjugates (AOCs) β-catenin TGF-β Receptor ADC Linker IFNAR Beta-lactamase 17β-HSD 11β-HSD Beta-secretase Dopamine β-hydroxylase PROTAC-Linker Conjugates for PAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P9999

Trontinemab RG6102; RO-7126209	Amyloid-β	Neurological Disease
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1 .

HY-P99859

Donanemab LY3002813	Amyloid-β	Neurological Disease
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .

HY-P990110

Lecanemab (Mouse IGG2a) 1 Publications Verification Mab158	Amyloid-β	Neurological Disease
Lecanemab (Mouse IGG2a) (Mab158) is a monoclonal antibody that targets soluble *β-amyloid* and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) almost abolishes Aβ accumulation in astrocytes and rescues neurons from Aβ-induced cell death. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimer's disease .

HY-P9967

Aducanumab BIIB037	Amyloid-β	Neurological Disease
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows blood-brain-barrier penetration, and can be used for Alzheimer's disease (AD) research .

HY-P99317

Solanezumab LY-2062430	Amyloid-β	Neurological Disease
Solanezumab (LY-2062430) is a humanized monoclonal IgG1 antibody directed against the mid-domain of the *amyloid-β* (Aβ) peptide. Solanezumab binds to the mid-domain of monomeric amyloid-beta to slow brain amyloid accumulation. Solanezumab can be used for the research of Alzheimer’s disease .

HY-P990109

Aducanumab (Mouse IGG2a)	Amyloid-β	Neurological Disease
Aducanumab (Mouse IGG2a) is a monoclonal antibody that selectively targets *aggregated amyloid-beta* (Aβ). The variable region of Aducanumab (Mouse IGG2a) is consistent with that of Aducanumab (HY-P9967), while the constant region is of Mouse IGG2a sequence. Aducanumab (Mouse IGG2a) has strong selectivity for Aβ fibrils with EC₅₀**s of >1 μM and 0.2 nM for monomeric Aβ_1-40 and fibrillar Aβ_1-42, respectively. Aducanumab (Mouse IGG2a) can be used for Alzheimer's disease (AD) research .

HY-P99216

Ponezumab 1 Publications Verification PF-04360365; RN 1219	Amyloid-β	Neurological Disease
Ponezumab (PF-04360365; RN 1219) is a humanized anti-amyloid-β (Amyloid-β) IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves the performance of mice in various learning and memory models. Ponezumab is applicable to the research of Alzheimer's disease .

HY-P99185

Bapineuzumab AAB-001	Amyloid-β	Neurological Disease
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .

HY-P991413

ZEB85	Trk Receptor ERK Akt p38 MAPK	Neurological Disease Inflammation/Immunology
ZEB85 is a human monoclonal antibody (mAb) targeting TrkB. ZEB85 activates TrkB and its downstream cascades, including the ERK, PLCγ, AKT, MAPK signaling pathways and cFOS expression, and enhances neuronal activity. ZEB85 prevents β-amyloid toxicity in cultured hippocampal neurons. ZEB85 is applicable to the research of Alzheimer's disease (AD) .

HY-P991480

ONC-841	Transmembrane Glycoprotein Tau Protein Amyloid-β	Neurological Disease Cancer
ONC-841 is a blood-brain barrier-permeable, humanized monoclonal antibody targeting SIGLEC10. As an immune checkpoint inhibitor, ONC-841 restores the functions of immune effector cells such as T cells and enhances anti-tumor immune responses by blocking inhibitory signals mediated by SIGLEC10. ONC-841 restores the phagocytic and migratory activities of microglia, and promotes the phagocytosis of *Amyloid-β* and Tau protein aggregates by microglia. ONC-841 is applicable to research related to solid tumors and Alzheimer's disease .

HY-P990301

Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2)	Amyloid-β	Neurological Disease
Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is a mouse-derived IgG2b λ type antibody inhibitor, targeting to *Amyloid-beta. Anti-Human/Mouse/Rat Amyloid-beta* Antibody (MOAB-2) recognizes unaggregated, oligomeric or fibrillar forms of Aβ42 and unaggregated Aβ40. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is selective for human Aβ42 over Aβ40, but not amyloid precursor protein (APP). Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) can immunostain human or rat and mouse tissue. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) can be used for detections of western blot, immunohistochemistry, immunofluorescence, immunoprecipitation and ELISA .

HY-P990078

Remternetug LY3372993	Amyloid-β	Neurological Disease
Remternetug (LY3372993) is a monoclonal antibody that targets pyroglutamylated amyloid β fibrils (N3pG-Aβ). Remternetug specifically binds to N3pG-Aβ, thereby clearing amyloid plaques in the brain and reducing amyloid burden. Remternetug can be used in research related to Alzheimer's disease .

HY-P990011

Sabirnetug ACU-193	Amyloid-β	Neurological Disease
Sabirnetug is a humanized IgG2κ antibody targeting the Amyloid-β A4 precursor protein.

HY-P991130

Dalidnetug	Amyloid-β	Neurological Disease
Dalidnetug is a humanized monoclonal antibody targeting human amyloid-beta precursor protein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .

HY-P991702

Merinetug	Amyloid-β	Neurological Disease
Merinetug is a humanized IgG1κ antibody targeting Amyloid beta/Aβ. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991168

Velaprumig	Amyloid-β CCR	Neurological Disease Inflammation/Immunology
Velaprumig is a monoclonal antibody targeting human CD99, CCL25, and anti-human Aβ (Aβ-47F). Velaprumig regulates immune cell migration and reduces β-amyloid-related pathological processes, exerting immunomodulatory and potential anti - Alzheimer's disease activities .

HY-P1787

β-Amyloid (4-10)	Amyloid-β	Neurological Disease
β-Amyloid (4-10) is an epitope for the polyclonal anti-Aβ(1-42) antibody, reduces amyloid deposition in a transgenic Alzheimer disease mouse model .

HY-P991535

PMN310	Amyloid-β	Neurological Disease
PMN310 is a monoclonal antibody targeting amyloid-β oligomers (AβO). PMN310 prevents AβO-induced memory loss and reduces synaptic loss and inflammation in vivo. PMN310 is potentially useful in Alzheimer's disease research .

HY-P991536

KHK6640	Amyloid-β	Neurological Disease
KHK6640 is a humanized anti-amyloid beta oligomer-specific antibody. KHK6640 demonstrates high potency and efficacy for cognitive improvement in several rodent Alzheimer’s models. KHK6640 can be studied in research for neurological diseases such as Alzheimer’s disease .

HY-P991101

Anti-Amyloid Beta Antibody (scFv59)	Amyloid-β	Neurological Disease
Anti-Amyloid Beta Antibody (scFv59) is a human antibody expressed in CHO cells, targeting *Amyloid-β. Anti-Amyloid* Beta Antibody (scFv59) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990332

Anti-Amyloid Beta Antibody (CNTO 2125) CNTO 2125	Amyloid-β	Inflammation/Immunology
Anti-Amyloid Beta Antibody (CNTO 2125) is a humanized antibody expressed in CHO cells, targeting Amyloid Beta/Aβ. Anti-Amyloid Beta Antibody (CNTO 2125) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Amyloid Beta Antibody (CNTO 2125) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P10628

β Amyloid (1-14), human	Amyloid-β	Neurological Disease
β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research .

HY-P991654

SAR228810	Amyloid-β	Neurological Disease
SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid β (Aβ) with a KD? of ?0.43 ?nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research .

HY-P992157

Anti-APP/Amyloid beta Antibody (3D6) murine version of Bapineuzumab	Amyloid-β	Neurological Disease
Anti-APP/Amyloid beta Antibody (3D6) is an antibody targeting β-amyloid protein (Aβ) containing free Asp1. Anti-APP/Amyloid beta Antibody (3D6) recognizes and binds to the amino acid epitope at positions 1-5 of β-amyloid protein with a free Asp1 residue. Anti-APP/Amyloid beta Antibody (3D6) serves as a detection antibody in immunoblot analysis. Anti-APP/Amyloid beta Antibody (3D6) is applicable to research related to Alzheimer's disease .

HY-P991534

PF-04382923	Amyloid-β	Neurological Disease
PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the *amyloid-β* peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .

HY-P990595

GSK-933776	Amyloid-β	Inflammation/Immunology
GSK-933776 is a humanized antibody expressed in CHO, targeting Amyloid Beta/Aβ. GSK-933776 has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.34 kDa. The isotype control for GSK-933776 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Cat. No.	Product Name	Target	Research Area

HY-P1787

β-Amyloid (4-10)	Amyloid-β	Neurological Disease
β-Amyloid (4-10) is an epitope for the polyclonal anti-Aβ(1-42) antibody, reduces amyloid deposition in a transgenic Alzheimer disease mouse model .

HY-P10628

β Amyloid (1-14), human	Amyloid-β	Neurological Disease
β Amyloid (1-14), human is a peptide fragment of β-amyloid protein (Aβ), which is obtained by hydrolysis of Aβ1-40 peptide by catalytic antibody light chain #7TR. β Amyloid (1-14), human can be used for Alzheimer's disease research .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9999

Trontinemab RG6102; RO-7126209	Amyloid-β	Neurological Disease
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1 .

HY-P99859

Donanemab LY3002813	Amyloid-β	Neurological Disease
Donanemab (LY3002813) is a humanized IgG1 monoclonal antibody directed at an N-terminal pyroglutamate amyloid beta (Aβ) epitope. Donanemab has the potential for early Alzheimer's disease research .

HY-P990110

Lecanemab (Mouse IGG2a) 1 Publications Verification Mab158	Amyloid-β	Neurological Disease
Lecanemab (Mouse IGG2a) (Mab158) is a monoclonal antibody that targets soluble *β-amyloid* and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IGG2a sequence. Lecanemab (Mouse IGG2a) almost abolishes Aβ accumulation in astrocytes and rescues neurons from Aβ-induced cell death. Lecanemab (Mouse IGG2a) holds promise for research in the field of Alzheimer's disease .

HY-P9967

Aducanumab BIIB037	Amyloid-β	Neurological Disease
Aducanumab (BIIB037) is a human monoclonal antibody that selectively targets aggregated amyloid-beta (Aβ). Aducanumab shows blood-brain-barrier penetration, and can be used for Alzheimer's disease (AD) research .

HY-P99317

Solanezumab LY-2062430	Amyloid-β	Neurological Disease
Solanezumab (LY-2062430) is a humanized monoclonal IgG1 antibody directed against the mid-domain of the *amyloid-β* (Aβ) peptide. Solanezumab binds to the mid-domain of monomeric amyloid-beta to slow brain amyloid accumulation. Solanezumab can be used for the research of Alzheimer’s disease .

HY-P990109

Aducanumab (Mouse IGG2a)	Amyloid-β	Neurological Disease
Aducanumab (Mouse IGG2a) is a monoclonal antibody that selectively targets *aggregated amyloid-beta* (Aβ). The variable region of Aducanumab (Mouse IGG2a) is consistent with that of Aducanumab (HY-P9967), while the constant region is of Mouse IGG2a sequence. Aducanumab (Mouse IGG2a) has strong selectivity for Aβ fibrils with EC₅₀**s of >1 μM and 0.2 nM for monomeric Aβ_1-40 and fibrillar Aβ_1-42, respectively. Aducanumab (Mouse IGG2a) can be used for Alzheimer's disease (AD) research .

HY-P99216

Ponezumab 1 Publications Verification PF-04360365; RN 1219	Amyloid-β	Neurological Disease
Ponezumab (PF-04360365; RN 1219) is a humanized anti-amyloid-β (Amyloid-β) IgG2 monoclonal antibody. Ponezumab reduces Aβ levels in the central nervous system and improves the performance of mice in various learning and memory models. Ponezumab is applicable to the research of Alzheimer's disease .

HY-P99185

Bapineuzumab AAB-001	Amyloid-β	Neurological Disease
Bapineuzumab is an anti-β-amyloid protein (APP) monoclonal antibody. Bapineuzumab is a humanized IgG1 that recognizes the N terminus of Aβ cleared plaques from the brains. Bapineuzumab can be used for the research of Alzheimer’s disease (AD) .

HY-P991413

ZEB85	Trk Receptor ERK Akt p38 MAPK	Neurological Disease Inflammation/Immunology
ZEB85 is a human monoclonal antibody (mAb) targeting TrkB. ZEB85 activates TrkB and its downstream cascades, including the ERK, PLCγ, AKT, MAPK signaling pathways and cFOS expression, and enhances neuronal activity. ZEB85 prevents β-amyloid toxicity in cultured hippocampal neurons. ZEB85 is applicable to the research of Alzheimer's disease (AD) .

HY-P991480

ONC-841	Transmembrane Glycoprotein Tau Protein Amyloid-β	Neurological Disease Cancer
ONC-841 is a blood-brain barrier-permeable, humanized monoclonal antibody targeting SIGLEC10. As an immune checkpoint inhibitor, ONC-841 restores the functions of immune effector cells such as T cells and enhances anti-tumor immune responses by blocking inhibitory signals mediated by SIGLEC10. ONC-841 restores the phagocytic and migratory activities of microglia, and promotes the phagocytosis of *Amyloid-β* and Tau protein aggregates by microglia. ONC-841 is applicable to research related to solid tumors and Alzheimer's disease .

HY-P990301

Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2)	Amyloid-β	Neurological Disease
Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is a mouse-derived IgG2b λ type antibody inhibitor, targeting to *Amyloid-beta. Anti-Human/Mouse/Rat Amyloid-beta* Antibody (MOAB-2) recognizes unaggregated, oligomeric or fibrillar forms of Aβ42 and unaggregated Aβ40. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) is selective for human Aβ42 over Aβ40, but not amyloid precursor protein (APP). Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) can immunostain human or rat and mouse tissue. Anti-Human/Mouse/Rat Amyloid-beta Antibody (MOAB-2) can be used for detections of western blot, immunohistochemistry, immunofluorescence, immunoprecipitation and ELISA .

HY-P990078

Remternetug LY3372993	Amyloid-β	Neurological Disease
Remternetug (LY3372993) is a monoclonal antibody that targets pyroglutamylated amyloid β fibrils (N3pG-Aβ). Remternetug specifically binds to N3pG-Aβ, thereby clearing amyloid plaques in the brain and reducing amyloid burden. Remternetug can be used in research related to Alzheimer's disease .

HY-P990011

Sabirnetug ACU-193	Amyloid-β	Neurological Disease
Sabirnetug is a humanized IgG2κ antibody targeting the Amyloid-β A4 precursor protein.

HY-P991130

Dalidnetug	Amyloid-β	Neurological Disease
Dalidnetug is a humanized monoclonal antibody targeting human amyloid-beta precursor protein (APP). Dalidnetug specifically binds to APP to reduce the production of amyloid-beta (Aβ), thus exerting the activity of clearing amyloid-beta. Dalidnetug is promising for research of Alzheimer's disease .

HY-P991702

Merinetug	Amyloid-β	Neurological Disease
Merinetug is a humanized IgG1κ antibody targeting Amyloid beta/Aβ. The corresponding isotype control is: Human IgG1 kappa, Isotype Control (HY-P99001) .

HY-P991168

Velaprumig	Amyloid-β CCR	Neurological Disease Inflammation/Immunology
Velaprumig is a monoclonal antibody targeting human CD99, CCL25, and anti-human Aβ (Aβ-47F). Velaprumig regulates immune cell migration and reduces β-amyloid-related pathological processes, exerting immunomodulatory and potential anti - Alzheimer's disease activities .

HY-P990081

Oloctinebart TB-006	Inhibitory Antibodies	Neurological Disease
Oloctinebart is a humanized immunoglobulin G4-kappa, *anti-LGALS3* monoclonal antibody. Oloctinebart is used for reduction of amyloid beta oligomers formation .

HY-P991535

PMN310	Amyloid-β	Neurological Disease
PMN310 is a monoclonal antibody targeting amyloid-β oligomers (AβO). PMN310 prevents AβO-induced memory loss and reduces synaptic loss and inflammation in vivo. PMN310 is potentially useful in Alzheimer's disease research .

HY-P991536

KHK6640	Amyloid-β	Neurological Disease
KHK6640 is a humanized anti-amyloid beta oligomer-specific antibody. KHK6640 demonstrates high potency and efficacy for cognitive improvement in several rodent Alzheimer’s models. KHK6640 can be studied in research for neurological diseases such as Alzheimer’s disease .

HY-P991101

Anti-Amyloid Beta Antibody (scFv59)	Amyloid-β	Neurological Disease
Anti-Amyloid Beta Antibody (scFv59) is a human antibody expressed in CHO cells, targeting *Amyloid-β. Anti-Amyloid* Beta Antibody (scFv59) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P990332

Anti-Amyloid Beta Antibody (CNTO 2125) CNTO 2125	Amyloid-β	Inflammation/Immunology
Anti-Amyloid Beta Antibody (CNTO 2125) is a humanized antibody expressed in CHO cells, targeting Amyloid Beta/Aβ. Anti-Amyloid Beta Antibody (CNTO 2125) features a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Anti-Amyloid Beta Antibody (CNTO 2125) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991654

SAR228810	Amyloid-β	Neurological Disease
SAR228810 is a humanized IgG4 monoclonal antibody inhibitor targeting amyloid β (Aβ) with a KD? of ?0.43 ?nM for protofibrillar Aβ over monomeric Aβ. SAR228810 significantly inhibits the brain amyloid plaque formation and oligomer-induced synaptic dysfunction and neurite loss. SAR228810 has significant protection against Aβ-mediated neuritotoxicity. MINT1526A can be used for Alzheimer’s disease imaging and immunotherapy research .

HY-P992157

Anti-APP/Amyloid beta Antibody (3D6) murine version of Bapineuzumab	Amyloid-β	Neurological Disease
Anti-APP/Amyloid beta Antibody (3D6) is an antibody targeting β-amyloid protein (Aβ) containing free Asp1. Anti-APP/Amyloid beta Antibody (3D6) recognizes and binds to the amino acid epitope at positions 1-5 of β-amyloid protein with a free Asp1 residue. Anti-APP/Amyloid beta Antibody (3D6) serves as a detection antibody in immunoblot analysis. Anti-APP/Amyloid beta Antibody (3D6) is applicable to research related to Alzheimer's disease .

HY-P990333

Anti-Amyloid Beta Antibody (DLX212) DLX212	Inhibitory Antibodies	Inflammation/Immunology
Anti-Amyloid Beta Antibody (DLX212) is a CHO-expressed human antibody that targets Amyloid Beta/Aβ. Anti-Amyloid Beta Antibody (DLX212) contains huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.74 kDa. The isotype control for Anti-Amyloid Beta Antibody (DLX212) can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991534

PF-04382923	Amyloid-β	Neurological Disease
PF-04382923 is a humanized IgG2Δa monoclonal antibody. PF-04382923 binds with high affinity to the free C-terminal regions of the *amyloid-β* peptides Aβ1-40 and Aβ1-42. PF-04382923 is indicated for the study of geographic atrophy (GA) associated with dry age-related macular degeneration (ARMD) .

HY-P990595

GSK-933776	Amyloid-β	Inflammation/Immunology
GSK-933776 is a humanized antibody expressed in CHO, targeting Amyloid Beta/Aβ. GSK-933776 has huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 145.34 kDa. The isotype control for GSK-933776 can be referenced as Human IgG1 kappa, Isotype Control (HY-P99001).

Host:	Mouse (2) Rabbit (7)
Reactivity:	Human (9) Rat (1) Mouse (7)
Application:	IHC-P (9) ICC/IF (2) IF-Tissue (7) IP (1) DotBlot (2) IHC-F (2) WB (9) ELISA (1)
Isotype:	IgG (7) IgG2b (2)
Conjugation:	Non-conjugated (9)
Clonality:	Monoclonal (8) Recombinant (6)
Modification:	Unmodified (8)

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P86747

	beta-Amyloid 1-42 Antibody (YA6439) Beta-Amyloid(1-42); A4; AAA; ABeta; ABPP; AD1; Alzheimers Disease Amyloid Protein; Amyloid B; Amyloid Beta A4 Protein Precursor; Amyloid Beta; Amyloid of Aging and Alzheimer Disease; APP; APPI; B Amyloid; Beta APP; Cerebral Vascular Amyloid Peptide; CTFgamma; CVAP; PN II; PN2; PreA4; Protease nexin II; A Beta; Amyloid 1-42.Aβ	WB, IHC-P, IHC-F, IF-Tissue	Human
	beta-Amyloid(1-42) Antibody (YA6439) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to beta-Amyloid(1-42).

HY-P86422

	beta-Amyloid Antibody (YA6114) APP; A4; AD1; Amyloid Beta A4 protein; ABPP; APPI; APP; Alzheimer disease Amyloid protein; Cerebral vascular Amyloid peptide; CVAP; PreA4; Protease nexin-II; PN-II; Aβ	WB, IHC-P, ICC/IF, IP, ELISA	Human, Mouse, Rat
	beta-Amyloid Antibody (YA6114) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta-Amyloid.

HY-P86747A

	beta-Amyloid 1-42 Antibody (YA6439)(PBS only) Beta-Amyloid(1-42); A4; AAA; ABeta; ABPP; AD1; Alzheimers Disease Amyloid Protein; Amyloid B; Amyloid Beta A4 Protein Precursor; Amyloid Beta; Amyloid of Aging and Alzheimer Disease; APP; APPI; B Amyloid; Beta APP; Cerebral Vascular Amyloid Peptide; CTFgamma; CVAP; PN II; PN2; PreA4; Protease nexin II; A Beta; Amyloid 1-42.Aβ	WB, IHC-P, IHC-F, IF-Tissue	Human
	beta-Amyloid(1-42) Antibody (YA6439) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to beta-Amyloid(1-42).

HY-P83754

	beta Amyloid 1-42 Antibody (YA3555) A4 Antibody; A4_HUMAN Antibody; AAA Antibody; ABeta Antibody; ABPP Antibody; AICD-50 Antibody; AICD-57 Antibody; AICD-59 Antibody; AID(50) Antibody; AID(57) Antibody; AID(59) Antibody; Alzheimer disease Amyloid protein Antibody; Amyloid intracellular domain 50 Antibody; Amyloid intracellular domain 57 Antibody; Amyloid intracellular domain 59 Antibody; APP Antibody; APPI Antibody; Beta Amyloid protein 42 Antibody; Beta APP42 Antibody; Beta-APP40 Antibody; Beta-APP42 Antibody; C31 Antibody; Cerebral vascular Amyloid peptide Antibody; CVAP Antibody; Gamma-CTF(50) Antibody; Gamma-CTF(57) Antibody; Gamma-CTF(59) Antibody; PN-II Antibody; PreA4 Antibody; Protease nexin-II Antibody; S-APP-alpha Antibody; S-APP-Beta Antibody Aβ	WB, IHC-P, IF-Tissue	Human, Mouse
	beta Amyloid 1-42 Antibody (YA3555) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta Amyloid 1-42.

HY-P83755

	beta Amyloid Antibody (YA3556) A4 Antibody; A4_HUMAN Antibody; AAA Antibody; ABeta Antibody; ABPP Antibody; AICD-50 Antibody; AICD-57 Antibody; AICD-59 Antibody; AID(50) Antibody; AID(57) Antibody; AID(59) Antibody; Alzheimer disease Amyloid protein Antibody; Amyloid intracellular domain 50 Antibody; Amyloid intracellular domain 57 Antibody; Amyloid intracellular domain 59 Antibody; APP Antibody; APPI Antibody; Beta Amyloid protein 42 Antibody; Beta APP42 Antibody; Beta-APP40 Antibody; Beta-APP42 Antibody; C31 Antibody; Cerebral vascular Amyloid peptide Antibody; CVAP Antibody; Gamma-CTF(50) Antibody; Gamma-CTF(57) Antibody; Gamma-CTF(59) Antibody; PN-II Antibody; PreA4 Antibody; Protease nexin-II Antibody; S-APP-alpha Antibody; S-APP-Beta Antibody; Aβ;	WB, IHC-P, ICC/IF, DotBlot	Human, Mouse
	beta Amyloid Antibody (YA3556) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta Amyloid.

HY-P83754A

	beta Amyloid 1-42 Antibody (YA3555)(PBS only) A4 Antibody; A4_HUMAN Antibody; AAA Antibody; ABeta Antibody; ABPP Antibody; AICD-50 Antibody; AICD-57 Antibody; AICD-59 Antibody; AID(50) Antibody; AID(57) Antibody; AID(59) Antibody; Alzheimer disease Amyloid protein Antibody; Amyloid intracellular domain 50 Antibody; Amyloid intracellular domain 57 Antibody; Amyloid intracellular domain 59 Antibody; APP Antibody; APPI Antibody; Beta Amyloid protein 42 Antibody; Beta APP42 Antibody; Beta-APP40 Antibody; Beta-APP42 Antibody; C31 Antibody; Cerebral vascular Amyloid peptide Antibody; CVAP Antibody; Gamma-CTF(50) Antibody; Gamma-CTF(57) Antibody; Gamma-CTF(59) Antibody; PN-II Antibody; PreA4 Antibody; Protease nexin-II Antibody; S-APP-alpha Antibody; S-APP-Beta Antibody Aβ	WB, IHC-P, IF-Tissue	Human, Mouse
	beta Amyloid 1-42 Antibody (YA3555) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta Amyloid 1-42.

HY-P83755A

	beta Amyloid Antibody (YA3556)(PBS only) A4 Antibody; A4_HUMAN Antibody; AAA Antibody; ABeta Antibody; ABPP Antibody; AICD-50 Antibody; AICD-57 Antibody; AICD-59 Antibody; AID(50) Antibody; AID(57) Antibody; AID(59) Antibody; Alzheimer disease Amyloid protein Antibody; Amyloid intracellular domain 50 Antibody; Amyloid intracellular domain 57 Antibody; Amyloid intracellular domain 59 Antibody; APP Antibody; APPI Antibody; Beta Amyloid protein 42 Antibody; Beta APP42 Antibody; Beta-APP40 Antibody; Beta-APP42 Antibody; C31 Antibody; Cerebral vascular Amyloid peptide Antibody; CVAP Antibody; Gamma-CTF(50) Antibody; Gamma-CTF(57) Antibody; Gamma-CTF(59) Antibody; PN-II Antibody; PreA4 Antibody; Protease nexin-II Antibody; S-APP-alpha Antibody; S-APP-Beta Antibody; Aβ;	WB, IHC-P, IF-Tissue, DotBlot	Human, Mouse
	beta Amyloid Antibody (YA3556) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta Amyloid.

HY-P83753

	beta Amyloid 1-40 Antibody (YA3554) A4 Antibody; AAA Antibody; ABeta Antibody; ABPP Antibody; AICD-50 Antibody; AICD-57 Antibody; AICD-59 Antibody; AID(50) Antibody; AID(57) Antibody; AID(59) Antibody; Alzheimer disease Amyloid protein Antibody; Amyloid intracellular domain 50 Antibody; Amyloid intracellular domain 57 Antibody; Amyloid intracellular domain 59 Antibody; APP Antibody; APPI Antibody; Beta Amyloid protein 42 Antibody; Beta APP42 Antibody; Beta-APP40 Antibody; Beta-APP42 Antibody; C31 Antibody; Cerebral vascular Amyloid peptide Antibody; CVAP Antibody; Gamma-CTF(50) Antibody; Gamma-CTF(57) Antibody; Gamma-CTF(59) Antibody; PN-II Antibody; PreA4 Antibody; Protease nexin-II Antibody; S-APP-alpha Antibody; S-APP-Beta Antibody; Aβ;	WB, IHC-P, IF-Tissue	Human, Mouse
	beta Amyloid 1-40 Antibody (YA3554) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta Amyloid 1-40.

HY-P83753A

	beta Amyloid 1-40 Antibody (YA3554)(PBS only) A4 Antibody; AAA Antibody; ABeta Antibody; ABPP Antibody; AICD-50 Antibody; AICD-57 Antibody; AICD-59 Antibody; AID(50) Antibody; AID(57) Antibody; AID(59) Antibody; Alzheimer disease Amyloid protein Antibody; Amyloid intracellular domain 50 Antibody; Amyloid intracellular domain 57 Antibody; Amyloid intracellular domain 59 Antibody; APP Antibody; APPI Antibody; Beta Amyloid protein 42 Antibody; Beta APP42 Antibody; Beta-APP40 Antibody; Beta-APP42 Antibody; C31 Antibody; Cerebral vascular Amyloid peptide Antibody; CVAP Antibody; Gamma-CTF(50) Antibody; Gamma-CTF(57) Antibody; Gamma-CTF(59) Antibody; PN-II Antibody; PreA4 Antibody; Protease nexin-II Antibody; S-APP-alpha Antibody; S-APP-Beta Antibody; Aβ;	WB, IHC-P, IF-Tissue	Human, Mouse
	beta Amyloid 1-40 Antibody (YA3554) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta Amyloid 1-40.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: